Myoview

Quick links to important sections

Myoview

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myoview

What is Myoview? (Overview)

Property Description
Active ingredient Tetrofosmin
Form Lyophilized powder for solution (Kit)
Pharmacological class Radiopharmaceutical, Diagnostic agent
Common use Myocardial perfusion imaging
Origin Synthetic

Myoview: A Diagnostic Radiopharmaceutical Agent

Myoview is a highly specialized, synthetic medicine classified as a radiopharmaceutical preparation and a diagnostic agent. This means its sole function is to assist doctors in obtaining precise images, rather than providing any therapeutic treatment for a disease. It belongs to the class of myocardial perfusion agents, serving as a critical tool in nuclear medicine for assessing the functional health of the heart muscle. Myoview is specifically differentiated by being clinically recognized for its image quality in certain diagnostic settings compared to older tracers, a feature supported by pharmacological studies published in nuclear medicine literature. The preparation is intended for adult patients undergoing diagnostic cardiac procedures.


Composition, Form, and General Purpose

The active component of Myoview is the chemical entity Tetrofosmin, which acts as a ligand that must be combined with the short-lived radioisotope Technetium-99m (^99mathrmmmathrmTc) to form the functional tracer. The preparation is provided as a lyophilized powder for solution in a kit for the preparation of an injection, which is reconstituted at the clinical site just before administration via the intravenous route. The quick, efficient process for preparing the final tracer is a key differentiating feature, essential due to the radioisotope's short half-life. The overarching purpose of this tracer is to create a visual map of the heart's function for diagnostic assessment. Tetrofosmin accumulates in the heart muscle. This localization facilitates the creation of a functional photograph, which helps doctors differentiate areas of healthy, perfused tissue from those experiencing inadequate blood supply, such as during the assessment of known or suspected coronary artery disease.

What side effects are possible with Myoview ?

The safety profile for Myoview is formally documented in government regulatory sources, which categorize adverse reactions by frequency and physiological system. This classification assists in understanding the officially recognized safety characteristics of the diagnostic agent.

Adverse Reaction Categories

Classification Examples of Reactions (by regulatory classification)
Common Headache, dizziness, nausea, and a metallic taste.
Uncommon Allergic reactions, flushing, altered sense of smell (parosmia), and injection site reactions (e.g., pain, burning).

Adverse reactions are grouped by System-Organ Classes, with documented effects involving Nervous System Disorders (headache, dizziness), Gastrointestinal Disorders (nausea, vomiting), and General Disorders and Administration Site Conditions.

Serious Adverse Reactions and Safety Constraints

The regulatory labeling documents that the agent can cause serious adverse reactions, particularly hypersensitivity and anaphylactic reactions. These rare but significant events have included reports of hypotension and dyspnoea.

As a radiopharmaceutical, Myoview is inherently associated with a risk from radiation exposure, a mandatory safety consideration for its class. Regarding specific populations, the safety and effectiveness of the agent have not been established in pediatric patients. For pregnant or lactating individuals, the official safety statements focus on the potential for radiation exposure to the fetus or breastfed child.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for Myoview (Technetium Tc99m Tetrofosmin Injection) defines overdosage primarily as an overexposure to radioactivity, as the quantity of the chemical component Tetrofosmin administered is extremely low. Pharmacological toxicity is not the major documented concern.


Overdose Manifestations and Outcomes

Regulatory documents do not list specific acute clinical signs or symptoms associated with a chemical overdose. The documented risks are related to the effects of ionizing radiation.

Type of Risk Official Regulatory Statement
Major Risk Excessive exposure to ionizing radiation.
Long-Term Outcomes Potential for cancer induction and hereditary defects.

Required Emergency Actions

Actions required for a radiation overdose focus on minimizing the absorbed dose. No specific antidote is documented in the official labeling.

  • Supportive Measure: In cases of overdosage of radioactivity, patients should be encouraged to perform frequent micturition (urination) and defaecation (bowel movement) to expedite radiation clearance.

  • Special Considerations: For patients with renal impairment or hepatic impairment, consideration is required due to the possibility of increased radiation exposure.

When to Seek Urgent Medical Help

While an acute symptom profile is absent for radiation overdose, the label emphasizes that immediate care is necessary for severe, acute hypersensitivity or anaphylactic reactions that may occur during administration. Advanced life support facilities are required to be available to manage such emergencies.

Therapeutic Uses of Myoview

What Myoview Treats: Main Uses and Benefits

Myoview is a specialized diagnostic radiopharmaceutical agent whose clinical utility is defined by the precise information it provides about heart health, which is essential for guiding treatment. It does not treat symptoms directly, but plays a role in managing patients with known or suspected heart disease.

Myoview is indicated for scintigraphic imaging of the myocardium to help delineate regions of abnormal blood flow. This diagnostic tool is applied in clinical settings that involve acute or unstable symptom patterns and is relevant for patients experiencing symptoms related to physical discomfort, such as chest pain (angina) or shortness of breath, that suggest restricted blood flow.


The agent is commonly used across conditions characterized by periods of heightened symptoms to evaluate three primary areas: Coronary Artery Disease (CAD), differentiation between reversible ischemia and infarction, and risk stratification. Guiding management is the overall objective.

“The primary benefit of this diagnostic tool is providing the data necessary to support clinical decision-making and manage conditions associated with symptomatic distress.”

Quick Fact: Supports Diagnostic Clarity

Myoview assists with maintaining functional stability by giving doctors the crucial information needed to formulate management plans, which may contribute to easing the overall symptom load by addressing the underlying cause of heart-related discomfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Myoview?

Population eligibility for Myoview (Technetium 99m Tc Tetrofosmin) is strictly defined by regulatory labeling based on age, reproductive status, and pre-existing sensitivities.

Approved and Restricted Populations

Population Group Eligibility Status (Regulatory Basis)
Adults (18+ years) Established Use; the medicine is indicated for this age group.
Pediatric Patients Not Recommended; safety and effectiveness have not been established in children and adolescents.
Pregnant Women Contraindicated in some regions; use is restricted and only advised if the potential diagnostic benefit outweighs the radiation risk to the fetus.
Lactating Women Use is Restricted; an interruption of breastfeeding is mandatory for a specific period (e.g., 60 hours in US labeling) after administration.
Hypersensitive Patients Not Recommended; patients with known hypersensitivity to tetrofosmin or kit components (like sodium hydrosulfite) should not receive the agent.

Condition-Based Limitations

Conditional use is required for certain patients. Those with renal or hepatic impairment require careful consideration due to the potential for increased radiation exposure. Caution is also advised for patients with pre-existing conditions such as hypotension or breathing problems, as the associated diagnostic procedure may exacerbate these states.

What should I know about interactions with other medicines?

Myoview is a diagnostic radiopharmaceutical, and its interaction profile is primarily defined by its regulatory status and the procedural context of its use, rather than traditional metabolic pathways.

Drug-Drug Interaction Status

Official regulatory documentation states that specific drug-drug interaction studies have not been formally performed. Consequently, there are no documented contraindicated combinations or label-based requirements for separating the administration timing of Myoview from other medicines. Clinical studies reported no interactions with concomitant medication. There are no official statements documenting pharmacokinetic interactions, such as those mediated by CYP enzymes or drug transporters, nor are there documented interactions with food, alcohol, or herbal products.

Influence on Diagnostic Integrity

The officially recognized interaction pattern involves the effect of co-administered cardiovascular medicines on the diagnostic outcome itself. Medicines that influence myocardial function or blood flow can affect the accuracy of the imaging results. These include common classes such as beta blockers, calcium antagonists (also known as calcium channel blockers), and nitrates. Co-administration of these agents can lead to a false negative result in the diagnosis of coronary artery disease.

Procedural Constraints

When the myocardial perfusion imaging procedure involves a pharmacologic stress agent (such as adenosine or dipyridamole), the use and administration of that agent must strictly adhere to its specific regulatory prescribing information.

Mechanism of Action

Physicochemical Targeting and Cellular Uptake

The active complex, Technetium-99m Tetrofosmin (^99mathrmmmathrmTc-Tetrofosmin), functions as a lipophilic cationic complex; its structure and positive charge dictate its mechanism of entry. The complex crosses the outer membrane of heart muscle cells (cardiomyocytes) via passive diffusion, a process driven by concentration and lipid solubility, with entry into the tissue directly proportional to the regional myocardial blood flow it receives.


Retention via Mitochondrial Membrane Potential

The primary biological target is the mitochondrial membrane inside the cardiomyocyte. Once inside the cell, the complex's positive charge causes it to be electrostatically trapped within the highly negative environment of the inner mitochondrial matrix . Since the maintenance of this large negative membrane potential is dependent on cell viability, the retained concentration of the tracer reflects both the blood supply (perfusion) and the viability of the tissue.


Coupling to Diagnostic Signal

The resulting physiological effect is a differential activity map of the myocardium. The accumulated gamma-ray-emitting isotope generates a signal proportional to the local perfusion and cellular health. This mechanism allows for the production of a visual output where areas of high blood flow and retained mitochondrial potential show high tracer activity, while areas of reduced flow or compromised potential show low activity.

Dosage and Administration Information

How Myoview Is Used: Official Administration Guidelines

Myoview (Tetrofosmin) is a radiopharmaceutical agent used strictly for diagnostic imaging, and its use is governed by highly specific administration protocols. The medication is not a self-administered treatment but is utilized entirely within a specialized clinical environment, typically a nuclear medicine department.


Administration Scope

Instruction Detail
Route of administration Administration is exclusively via intravenous (IV) injection.
Dosing schedule The administered dose ranges from 185 to 1200 MBq (5 to 32.4 mCi) of the ^99mathrmmmathrmTc-labeled solution for each injection. The specific dose is tailored to the imaging equipment and protocol being used.
Frequency and Schedule Use follows a dual injection protocol for myocardial perfusion imaging, requiring two separate administrations: one injection for rest conditions and another for stress conditions, which may occur on the same or separate days.
Preparation requirements The lyophilized powder kit must be reconstituted at the clinical site with Technetium-99m (^99mathrmmmathrmTc) to form the functional tracer. The prepared solution must be used within 12 hours of reconstitution.
Procedural conditions The injection is typically followed by an intravenous saline flush. No specific dosage adjustment is required for older adults in the absence of explicit, documented clinical changes.

Procedural Structure of Use

Official instructions establish a structured, short-duration procedure rather than a continuous regimen. The preparation of the tracer solution and its administration by intravenous route must be executed by trained professionals in a specialized setting. This two-part injection schedule ensures the appropriate capture of diagnostic information under both rest and stress conditions as required by the clinical protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Myoview (Tetrofosmin)


Evidence for Use in Myocardial Perfusion Imaging (MPI) for Coronary Artery Disease (CAD)

Research examining Myoview’s diagnostic performance for identifying abnormal blood flow patterns in the heart muscle associated with Coronary Artery Disease (CAD) has been conducted primarily through open-label, multi-center clinical trials and comparison studies. These studies were applied in populations of adult patients with existing heart disease or those experiencing symptoms that suggested restricted blood flow. The main goal was to measure the diagnostic accuracy of the images by comparing the visualization of perfusion defects to a definitive reference standard, such as coronary angiography. Studies monitored outcomes related to the clarity and interpretability of the images and examined the results of Myoview in comparison to established imaging agents (such as Thallium-201).

However, the initial regulatory trials supporting the authorization of Myoview were often open-label, and the core studies included a small overall sample size. Research has also not yet fully characterized the agent’s performance in determining the exact size and location of regional blood flow abnormalities in certain high-risk patient populations.


Evidence for the Assessment of Left Ventricular (LV) Function

Research also explored using Myoview, combined with Gated SPECT (GSPECT) techniques, to assess the function of the heart's main pumping chamber, the Left Ventricle (LV). These were method comparison trials, which sought to determine if Myoview GSPECT could accurately measure key functional metrics like the Left Ventricular Ejection Fraction (LVEF) and the movement of the heart muscle wall, comparing results against the established MUGA blood pool imaging method. Findings indicate that the LVEF and wall motion measurements obtained using Myoview GSPECT showed an acceptable level of agreement and correlation when directly compared to the MUGA reference standard in the study populations.


Long-Term Research and Follow-up for Prognostic Value

While most core diagnostic trials were short-term comparisons, the broader evidence base includes observational studies that have examined the relationship between Myoview scan findings and patient outcomes over an extended duration. These studies monitored groups of patients for defined time intervals, sometimes for one year or more, to see how the initial imaging results correlated with the occurrence of major cardiac events. This research explored the tool's use in risk stratification, and this evidence was used to evaluate the prognostic value of the diagnostic information provided by Myoview.

Key Studies & References

  1. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease

Frequently Asked Questions (FAQ)

Common questions about Myoview (FAQ)

Q: How long does the Myoview substance stay in my system after the test?

The majority of the tracer leaves the body within the first two days following the injection. According to official regulatory documents, approximately 66% of the injected activity is eliminated within 48 hours. This material leaves the body primarily through the urine and feces.

Q: Is it safe to have a Myoview scan if I'm taking blood thinners like Warfarin?

Specific drug-drug interaction studies have not been formally performed for Myoview, and official product information lists no documented contraindicated combinations with other medications. However, it is important to inform your healthcare provider about all medicines, as drugs that affect the heart's function or blood flow can sometimes influence the final diagnostic results of the scan.

Q: How is Myoview different from Thallium stress tests?

Myoview uses a different radioactive tracer called Technetium-99m, which has a shorter half-life of about 6 hours compared to the older Thallium-201 agent. Clinical studies conducted for regulatory approval found that Myoview and Thallium-201 provided comparable diagnostic accuracy when used for assessing blood flow to the heart muscle.

Q: Is Myoview considered a radioactive substance, and if so, is it safe?

Yes, Myoview is classified as a radiopharmaceutical, meaning it contains a small, controlled amount of radioactive material. Official information states that it is associated with a necessary risk from radiation exposure, which is minimized by the short half-life of the tracer and the low dose used for diagnosis. In diagnostic nuclear medicine, this type of procedure is performed when the healthcare team determines the diagnostic benefit is greater than the associated risks.

Q: Can Myoview make me feel dizzy or tired the day of the test?

Adverse reaction data from official sources lists dizziness and headache as common side effects that people may feel after receiving the injection. Additionally, weakness or a lack of energy (asthenia) has been reported, particularly when Myoview is used alongside a pharmacological stress agent.

Q: Can I take my usual vitamins or supplements before a Myoview procedure?

While regulatory documents do not list specific interactions with vitamins or supplements, it is important to inform your medical team about all products you are taking. This information is needed because some substances may have an unfavorable influence on the diagnostic test. Healthcare providers often provide specific instructions for any required adjustments.

Q: What types of over-the-counter pain relievers might interact with Myoview?

Official information does not document specific pharmacokinetic interactions with common over-the-counter (OTC) pain relievers. However, for diagnostic accuracy, it is important to inform your doctor about all medicines, including OTC products, as any drug that affects blood flow to the heart could potentially influence the scan's results.

Q: Do caffeine or energy drinks affect the results of a Myoview test?

Yes, caffeine can significantly affect the results of the test, especially if a pharmacologic (drug-induced) stress test is planned. Patients are typically instructed to avoid all caffeine-containing foods, beverages (including coffee, tea, and colas), and energy drinks for a specific period, generally 12 to 24 hours before the procedure.

Q: Is Myoview suitable for patients with diabetes?

Diabetes is not listed as a contraindication for Myoview in regulatory documents. However, patients with diabetes are often given specialized protocols regarding fasting and medication timing prior to the procedure. Following these specialized protocols helps to ensure image quality and accurate results.

Q: How quickly is the radioactivity from Myoview eliminated from the body?

The radioactive component used with Myoview, Technetium Tc 99mathrmm, has a physical half-life of approximately 6.03 hours. This means half of the material decays every 6 hours. About two-thirds of the administered activity is eliminated from the body within the first 48 hours after the injection.

Q: How long does the whole Myoview procedure usually take?

The total duration of the myocardial perfusion imaging procedure can vary based on whether a one-day or two-day protocol is used. However, the complete two-part test (injections for rest and stress conditions) often requires a total time of about 3 to 4 hours to complete, including waiting periods between the injections and imaging.

Q: What is the typical 'uptake time' after the Myoview injection?

The tracer is rapidly absorbed by the heart muscle, reaching its maximum concentration in the tissue in about 5 minutes after the injection. Imaging typically begins relatively quickly, sometimes as soon as 15 minutes after the administration of the agent.

Q: What kind of preparation is needed the night before a Myoview test?

Preparation often begins the night before the test. This frequently includes specific fasting requirements and, most critically, following a strict instruction to stop consuming all caffeine-containing products 12 to 24 hours prior to the test.

Q: Can I drive myself home after receiving Myoview?

Official information lists adverse reactions such as dizziness, which could temporarily impair your ability to drive. Furthermore, the stress portion of the test may cause symptoms. For these reasons, patients are generally encouraged to arrange for someone else to drive them home after the procedure.

Q: Why is it important to avoid certain medications before the test?

It is important to avoid certain medications, especially those affecting the heart like beta blockers or nitrates, because they can influence the diagnostic outcome. According to regulatory sources, taking these medicines could lead to a 'false negative result,' meaning the scan might miss important signs of coronary artery disease.

Q: What does a 'normal' result look like after a Myoview scan?

A normal result means the scan shows the radiotracer is distributed uniformly throughout all the walls of the heart’s main pumping chamber (the left ventricle). This uniform distribution is interpreted as evidence of good, adequate blood flow, or perfusion, to all areas of the heart muscle.

Q: How soon after a Myoview procedure can I travel by plane?

There is no official travel restriction, but the radioactive agent may be detected by radiation screening systems at airports or border crossings for up to 24 to 48 hours. If you plan to travel by air or cross an international border within this period, patients are often advised to notify the clinic staff to request written documentation of the procedure.

Q: Do I need to wear specific clothing for the Myoview scan?

Patients are generally advised to wear comfortable clothing. It is often recommended to avoid clothing that contains large metal snaps, zippers, or underwires, as these metallic objects can interfere with the scanner and potentially reduce the quality of the diagnostic images.

Q: What if the Myoview injection site is red or sore afterwards?

Uncommon side effects listed in official information include reactions at the injection site, such as pain, burning, or redness. If you experience persistent redness, swelling, or pain at the site where you received the injection, it is recommended to inform the medical staff.

Q: Does Myoview show blockages in the heart arteries?

Myoview is used to create a functional image of the heart, showing patterns of blood flow (perfusion). It detects areas of the heart muscle that are not receiving enough blood, a condition often caused by blockages. However, it provides an image of the functional effect, not a direct, anatomical picture of the blockage itself.

Q: Are Myoview scans reliable for detecting early-stage heart disease?

Myoview is a well-established diagnostic tool used to evaluate the symptoms and risk of patients who have known or suspected Coronary Artery Disease (CAD). The scan assesses current functional blood flow and tissue viability to help the medical team in diagnosis and risk assessment.

Q: Is it okay to exercise on the day of my Myoview procedure?

The procedure itself is designed to include a planned stress component, which may involve exercise on a treadmill or bike. Beyond the stress portion of the test, patients are generally advised to avoid any further strenuous physical activity for the rest of the day.

Q: Will I be monitored continuously after the Myoview injection?

Yes, continuous monitoring is standard, especially for the stress phase of the test. Blood pressure, heart rate, and an electrocardiogram (ECG) are typically monitored before, during, and after the injection and stress test to ensure patient safety and accurately capture the diagnostic data.

Q: Why do some people need two separate injections of Myoview?

The use of two separate administrations is required by the official dual injection protocol for myocardial perfusion imaging. This allows one set of images to be captured under resting conditions and a second set to be captured during stress conditions, providing a critical side-by-side comparison for diagnosis.

Q: Can Myoview be used for imaging parts of the body other than the heart?

The regulatory indications for Myoview are specific and limited to diagnostic imaging of the heart muscle (Myocardial Perfusion Imaging) and the assessment of the heart's main pumping chamber (left ventricular function).

Q: Are there dietary restrictions after the Myoview procedure is finished?

Following the procedure, there are usually no dietary restrictions other than those related to minimizing radiation exposure. Patients are encouraged to drink plenty of non-caffeinated fluids and eat a light meal to help the body eliminate the remaining radioactive material.

Q: Is the Myoview injection painful?

The agent is administered through an intravenous injection, which is similar to a blood draw. While the injection itself is usually brief, the regulatory safety profile lists injection site reactions, including pain or a burning sensation, as an uncommon side effect.

Q: What is the typical half-life of the radioactive component in Myoview?

The radioactive component of the tracer, Technetium Tc 99mathrmm, has a physical half-life of approximately 6.03 hours. This short half-life is intentional, allowing the tracer to be eliminated from the body relatively quickly.

Q: Why are people told to empty their bladder frequently after the test?

Official precautions instruct patients to empty their bladder (void) frequently after the examination is completed and to maintain good hydration. This practice is necessary to help minimize the radiation dose to the bladder wall as the material is eliminated from the body.

Q: Does having a high BMI affect the quality of the Myoview scan results?

Clinical guidelines indicate that diagnostic-quality imaging is achievable for most patients, including those with a high BMI. Specialized techniques, such as using a higher tracer dose or incorporating attenuation correction, may be used by the medical team to overcome any potential image quality issues related to body size.

How should Myoview be stored and disposed of?

Storage and Disposal Requirements for Myoview (Technetium Tc 99m Tetrofosmin)

Official regulations require Myoview to be stored under precise, temperature-controlled conditions to maintain its stability. The unreconstituted kit (lyophilized powder) must be stored in its original package to protect it from light and kept in a refrigerator at 2 C to 8 C (36 F to 46 F). The reconstituted injection has a wider storage range of 2 C to 25 C (36 F to 77 F), but must not freeze and must be used within 12 hours of preparation. The medicine must also be stored out of the sight and reach of children.

Due to its classification as a radiopharmaceutical, all disposal of unused product and contaminated materials must follow specific procedures. Disposal must be handled as radioactive waste via an authorized route, in accordance with the regulations set by the competent official authority, such as the Nuclear Regulatory Commission (NRC).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Myoview  found in:

A-Z Index: